Abstract
BackgroundThe net health benefit of using antipsychotics in children and adolescents with ASD is unclear. This review was performed to provide the evidence necessary to inform the Italian national guidelines for the management of ASD.MethodsWe performed a systematic review of randomized controlled trials (RCTs) comparing antipsychotics versus placebo for the treatment of ASD in children and adolescents. For efficacy, acceptability and safety we considered outcomes evaluated by the guideline panel critical and important for decision-making. Continuous outcomes were analyzed by using standardized mean difference (SMD), and dichotomous outcomes by calculating the risk ratio (RR), with their 95% confidence interval (95% CI). Data were analyzed using a random effects model. We used the Cochrane tool to assess risk of bias of included studies. Certainty in the evidence of effects was assessed according to the GRADE approach.ResultsWe included 21 RCTs with 1,309 participants, comparing antipsychotics to placebo. Antipsychotics were found effective on “restricted and repetitive interests and behaviors” (SMD − 0.21, 95% CI − 0.35 to − 0.07, moderate certainty), “hyperactivity, inattention, oppositional, disruptive behavior” (SMD − 0.67, 95% CI − 0.92 to − 0.42, moderate certainty), “social communication, social interaction” (SMD − 0.38, 95% CI − 0.59 to − 0.16, moderate certainty), “emotional dysregulation/irritability” (SMD − 0.71, 95% CI − 0.98 to − 0.43, low certainty), “global functioning, global improvement” (SMD − 0.64, 95% CI − 0.96 to − 0.33, low certainty), “obsessions, compulsions” (SMD − 0.30, 95% CI − 0.55 to − 0.06, moderate certainty). Antipsychotics were not effective on “self-harm” (SMD − 0.14, 95% CI − 0.58 to 0.30, very low certainty), “anxiety” (SMD − 0.38, 95% CI − 0.82 to 0.07, very low certainty). Antipsychotics were more acceptable in terms of dropout due to any cause (RR 0.61, 95% CI 0.48 to 0.78, moderate certainty), but were less safe in terms of patients experiencing adverse events (RR 1.19, 95% CI 1.07 to 1.32, moderate certainty), and serious adverse events (RR 1.07, 95% CI 0.48 to 2.43, low certainty).ConclusionsOur systematic review and meta-analysis found antipsychotics for children and adolescents with ASD more efficacious than placebo in reducing stereotypies, hyperactivity, irritability and obsessions, compulsions, and in increasing social communication and global functioning. Antipsychotics were also found to be more acceptable, but less safe than placebo.
Highlights
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by persistent impairments in reciprocal social communication and social interactions along with the presence of restricted, repetitive patterns of behaviors, interests, or activities [1]
An observational study reported a high incidence of multiple treatment failure when children and adolescents with comorbid ASD and spectrum disorders (SSD) are treated with antipsychotics [12]
Results and overall certainty of evidence Forest plots for the main analyses are shown in Additional file 5, while the GRADE evidence profile is shown in Additional file 8
Summary
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by persistent impairments in reciprocal social communication and social interactions along with the presence of restricted, repetitive patterns of behaviors, interests, or activities [1]. No pharmacological treatment has currently shown to be effective for the treatment of the core symptoms of ASD. Pharmacological treatments, combined with psychological interventions, are directed at the treatment of associated symptoms (such as irritability) or coexisting psychiatric conditions (e.g. attention deficit disorder, oppositional disorder, schizophrenia spectrum disorders), which are frequent in patients with ASD [7]. Antipsychotics are used to treat associated comorbidities, such as schizophrenia spectrum disorders (SSD) and behavior disorders [8, 9]. An observational study reported a high incidence of multiple treatment failure when children and adolescents with comorbid ASD and SSD are treated with antipsychotics [12]. The net health benefit of using antipsychotics in children and adolescents with ASD is unclear.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
